Additionally, a combination of HSP70 inhibitors and proteasome inhibitors suppressed tumor growth with a greater efficiency than single-agent treatments in melanoma and multiple myeloma [121,173,174]. This evidence concerns the gene HSPA1A and plasma cell myeloma.